Messenger

EQS-News: SCHOTT Pharma delivers on 2023 targets and continues profitable growth trajectory

Retrieved on: 
Tuesday, January 30, 2024

“With our 2023 results, we have delivered on all our targets and have proven that SCHOTT Pharma is a highly profitable business.

Key Points: 
  • “With our 2023 results, we have delivered on all our targets and have proven that SCHOTT Pharma is a highly profitable business.
  • We will continue to benefit from key pharma trends and the overall market growth for injectable drugs”, said Almuth Steinkühler, CFO of SCHOTT Pharma.
  • In 2023, SCHOTT Pharma continued to deliver on its strategy and achieved several milestones along the pillars expansion and innovation.
  • On the innovation side, SCHOTT Pharma successfully introduced two leading innovations to the market that serve the pharma megatrends Glucagon-like peptide-1 (GLP-1) and mRNA.

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

Retrieved on: 
Monday, January 29, 2024

The collaboration will explore combining TransCode’s proprietary TTX delivery platform with Debiopharm’s expertise in targeted drug delivery to co-develop targeted nucleic acid therapeutics for cancer.

Key Points: 
  • The collaboration will explore combining TransCode’s proprietary TTX delivery platform with Debiopharm’s expertise in targeted drug delivery to co-develop targeted nucleic acid therapeutics for cancer.
  • TransCode’s TTX platform will serve as a backbone for development of antigen-selective nucleic acid delivery vehicles for targeted cancer therapeutics.
  • Specializing in the manufacturing and development of oncology and antibiotic therapies, Debiopharm entered this research collaboration to test the development of new targeted nucleic acid delivery modalities.
  • For TransCode, being able to collaborate with Debiopharm on an innovative project with the potential impact of targeted nucleic acid-based cancer therapeutics, represents a pivotal point for our company.”
    Financial terms were not disclosed.

Gov. Holcomb announces Meta to build an $800M Data Center Campus in Indiana

Retrieved on: 
Thursday, January 25, 2024

JEFFERSONVILLE, Ind., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Governor Eric J. Holcomb, board chairman for the Indiana Economic Development Corporation, joined executives of Meta Platforms Inc. (NASDAQ: META) today as the company announced plans to establish a new $800 million data center campus in Indiana.

Key Points: 
  • JEFFERSONVILLE, Ind., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Governor Eric J. Holcomb, board chairman for the Indiana Economic Development Corporation, joined executives of Meta Platforms Inc. (NASDAQ: META) today as the company announced plans to establish a new $800 million data center campus in Indiana.
  • “Today is a great day for Indiana and for our southeast region as we welcome another major investment to the River Ridge Commerce Center,” Gov.
  • Meta is starting construction this month and expects the data center to be operational in 2026.
  • We are committed to playing a positive role here and investing in the community's long-term vitality,” said Brad Davis, director of data center community and economic development at Meta.

Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2

Retrieved on: 
Wednesday, January 24, 2024

SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, today announced that Capricor’s proprietary StealthX™ exosome-based multivalent vaccine (StealthX™ vaccine) for the prevention of SARS-CoV-2 has been selected to be part of Project NextGen, an initiative by the U.S. Department of Health and Human Services to advance a pipeline of new, innovative vaccines providing broader and more durable protection for COVID-19. As part of Project NextGen, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will conduct a Phase 1 clinical study with Capricor’s StealthX™ vaccine, subject to regulatory approval. NIAID's Division of Microbiology and Infectious Diseases (DMID) would oversee the study.

Key Points: 
  • As part of Project NextGen, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will conduct a Phase 1 clinical study with Capricor’s StealthX™ vaccine, subject to regulatory approval.
  • We view the NIH SARS-CoV-2 project as the first clinical step towards development of a next generation vaccine platform that may be extended to other infectious diseases.
  • Our platform is designed to combine the speed of response of an mRNA vaccine with the potential efficacy of a protein vaccine.
  • Further, our StealthX™ vaccine is free of both adjuvant and lipid nanoparticles and in preclinical studies has generated a strong immune response at low doses.

Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Retrieved on: 
Friday, January 19, 2024

SOUTH SAN FRANCISCO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that the United States Biomedical Advanced Research and Development Authority (BARDA) has awarded the Company $9.27 million to fund preparation for a 10,000 subject Phase 2b clinical study evaluating Vaxart’s oral pill XBB COVID-19 vaccine candidate against an approved mRNA vaccine comparator.

Key Points: 
  • “We are very honored to receive this BARDA award, which will support the innovative approach of our oral pill vaccine platform,” said Dr. Michael Finney, Vaxart’s Interim Chief Executive Officer.
  • “We believe our oral pill vaccine platform may ultimately hold the promise of revolutionizing how we fight pandemics and how we vaccinate against several infectious diseases.
  • Second, our previous research on other vaccine constructs found Vaxart’s oral pill vaccine to be cross-reactive against all tested SARS-CoV-2 variants and to trigger long-lasting immune responses, potentially offering broader, longer protection than the current first-generation vaccines.
  • Vaxart’s oral pill vaccine platform provides many of the features desired by BARDA, such as generating mucosal immunity and providing a cross-reactive response to many COVID variants.

Genflow Biosciences Partners with Revatis SA and EXO Biologics in Groundbreaking Aging Research, Fueled by Two Major Research Grants

Retrieved on: 
Thursday, January 18, 2024

Continued receipt of the grants by Genflow is dependent on the parties meeting predefined criteria each applicable year.

Key Points: 
  • Continued receipt of the grants by Genflow is dependent on the parties meeting predefined criteria each applicable year.
  • Genflow, together with Revatis SA, has launched a 3-year sarcopenia research program, generously funded by new grants totalling 1.34 million euros.
  • This collaborative effort aims to expand and diversify Genflow's research pipeline, addressing this growing concern as the global population ages.
  • With the support of our partners and the backing of these two grants, we are poised to make meaningful advancements in the field of longevity."

Entos Pharmaceuticals Launches GMP Clinical Manufacturing Facility in Carlsbad, California

Retrieved on: 
Thursday, January 25, 2024

Entos Pharmaceuticals (Entos), a clinical-stage biotechnology company developing genetic medicines with its proprietary Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform, today announced the launch of its new Good Manufacturing Practices (GMP) manufacturing facility in Carlsbad, California.

Key Points: 
  • Entos Pharmaceuticals (Entos), a clinical-stage biotechnology company developing genetic medicines with its proprietary Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform, today announced the launch of its new Good Manufacturing Practices (GMP) manufacturing facility in Carlsbad, California.
  • View the full release here: https://www.businesswire.com/news/home/20240125096146/en/
    Entos Pharmaceuticals GMP Manufacturing Facility; Photo credit: Sean Hawkins, Facility Manager
    The state-of-the-art facility features 20,000 square feet of dedicated manufacturing space, including a lipid formulation production suite with additional suites dedicated to mRNA and plasmid DNA manufacturing.
  • “The successful commissioning of the site, followed by GMP batch manufacturing, exemplifies the potential of our facility.
  • The launch of this new Entos facility is a key step in the company’s global manufacturing strategy as it looks to establish a future manufacturing site in Edmonton, Alberta, Canada, to enable the commercial manufacturing of emerging transformative medicines for Entos and its valued partners.

BIO-TECHNE'S ADVANCED CELL DIAGNOSTICS (ACD) SETS NEW STANDARD IN SPATIAL BIOLOGY WITH PROTEASE-FREE RNASCOPE MULTIOMICS

Retrieved on: 
Monday, January 29, 2024

MINNEAPOLIS, Jan. 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), a Bio-Techne spatial biology brand, has set a new standard with the development of a next-generation, protease-free RNAscope spatial multiomics workflow. Optimized for same-slide detection of protein and RNA biomarkers with unparalleled sensitivity and tissue morphology, the newly developed RNAscope spatial multiomics workflow is compatible with both manual and automated assays. ACD's novel protease-free RNAscope workflow is incorporated in Bio-Techne's recently announced best-in-class multiomics application on Lunaphore's COMET platform.

Key Points: 
  • Advanced Cell Diagnostics (ACD), a Bio-Techne spatial biology brand, achieves technical breakthrough enabling protease-free, same-slide detection of protein and RNA biomarkers using industry-leading RNAscope™ technology.
  • MINNEAPOLIS, Jan. 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD) , a Bio-Techne spatial biology brand, has set a new standard with the development of a next-generation, protease-free RNAscope spatial multiomics workflow.
  • Optimized for same-slide detection of protein and RNA biomarkers with unparalleled sensitivity and tissue morphology, the newly developed RNAscope spatial multiomics workflow is compatible with both manual and automated assays.
  • ACD's novel protease-free RNAscope workflow is incorporated in Bio-Techne's recently announced best-in-class multiomics application on Lunaphore's COMET platform.

Elegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen’s Cell-Free DNA Production Technology

Retrieved on: 
Wednesday, January 24, 2024

Elegen, a leader in DNA manufacturing innovation, today announced a collaboration and licensing agreement with GSK (LSE/NYSE: GSK) to enable its use of Elegen’s proprietary cell-free DNA manufacturing technology in the development of GSK’s vaccines and medicines.

Key Points: 
  • Elegen, a leader in DNA manufacturing innovation, today announced a collaboration and licensing agreement with GSK (LSE/NYSE: GSK) to enable its use of Elegen’s proprietary cell-free DNA manufacturing technology in the development of GSK’s vaccines and medicines.
  • The terms of the agreement include upfront fees and purchase commitments of Elegen’s ENFINIA DNA to support GSK’s development of medicines and vaccines, including RNA vaccines.
  • Elegen is also eligible to receive both near-term milestone payments relating to the development of new product features and a potential equity investment in Elegen by GSK.
  • This collaboration will expand our offering to include the clinical production of genetic medicines potentially including mRNA, cell and viral gene therapies.”

Strand Therapeutics Receives IND Clearance for Programmable mRNA Therapy STX-001 to Treat Solid Tumors

Retrieved on: 
Monday, January 22, 2024

“STX-001 has the potential to become the first programmable mRNA therapy in oncology,” said Jake Becraft, Ph.D., CEO & Co-Founder, Strand Therapeutics.

Key Points: 
  • “STX-001 has the potential to become the first programmable mRNA therapy in oncology,” said Jake Becraft, Ph.D., CEO & Co-Founder, Strand Therapeutics.
  • “We’re thrilled to receive IND clearance to advance our program into patients, which represents an important milestone for our company.
  • STX-001 represents a promising new approach for the treatment of solid tumors.
  • We’re excited to continue evaluating our programmable mRNA technology across a number of therapeutic areas.”
    STX-001 shows promise as a new approach to improve the efficacy of current immunotherapies for solid tumors.